Skip to main content
. 2019 May 28;195(10):894–901. doi: 10.1007/s00066-019-01477-y

Fig. 2.

Fig. 2

Quality of life scores for the urinary (a), bowel (b), hormonal treatment-related symptoms (c) and sexual functioning (d) domains. RT radiotherapy, mos months; LR low risk, IR intermediate risk, HR high risk. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001